Mesoblast Bilan de santé

Santé financière contrôle des critères 4/6

Mesoblast possède un total de capitaux propres de $480.4M et une dette totale de $114.3M, ce qui porte son ratio d'endettement à 23.8%. Son actif total et son passif total sont $669.2M et de $188.8M.

Informations clés

23.8%

Ratio d'endettement

US$114.35m

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$62.96m
Fonds propres	US$480.36m
Total du passif	US$188.80m
Total des actifs	US$669.15m

Mises à jour récentes de la santé financière

Recent updates

Mesoblast's remestemcel-L reduces mortality by 46% in patients under age 65 with COVID-19 ARDS

Apr 30

Mesoblast issues FQ2 operational and financial update

Jan 29

Mesoblast's rexlemestrocel-l reduces heart attacks, strokes

Jan 11

Mesoblast: The Future Looks Bleak

Dec 24

Mesoblast fails to meet primary endpoint of reduction in recurrent non-fatal heart failure events

Dec 15

Mesoblast cell therapy Fast Track'd for COVID-19-related acute respiratory distress syndrome; shares up 14%

Dec 02

Mesoblast EPS beats by $0.22, misses on revenue

Nov 19

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de MESO ( $86.5M ) dépassent ses passifs à court terme ( $73.2M ).

Passif à long terme: Les actifs à court terme de MESO ( $86.5M ) ne couvrent pas ses passifs à long terme ( $115.6M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: Le ratio dette nette/capitaux propres de MESO ( 10.7% ) est considéré comme satisfaisant.

Réduire la dette: Le ratio d'endettement de MESO est passé de 16.9% à 23.8% au cours des 5 dernières années.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: MESO dispose d'une piste de trésorerie suffisante pour plus d'un an sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: MESO devrait disposer d'une marge de trésorerie suffisante pour 11 mois sur la base des estimations de flux de trésorerie disponible, mais a depuis levé des capitaux supplémentaires.

Découvrir des entreprises saines

Analyse de l'entreprise et données financières

Données	Dernière mise à jour (heure UTC)
Analyse de l'entreprise	2024/12/22 17:17
Cours de l'action en fin de journée	2024/12/20 00:00
Les revenus	2024/06/30
Revenus annuels	2024/06/30

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

Paquet	Données	Cadre temporel	Exemple de source américaine ^*
Finances de l'entreprise	10 ans	Compte de résultat Tableau des flux de trésorerie Bilan	Formulaire 10-K de la SEC Formulaire 10-Q de la SEC
Estimations consensuelles des analystes	+3 ans	Prévisions financières Objectifs de prix des analystes	Rapports de recherche des analystes Blue Matrix
Prix du marché	30 ans	Cours des actions Dividendes, scissions et actions	Données de marché ICE Formulaire S-1 de la SEC
Propriété	10 ans	Actionnaires principaux Délits d'initiés	Formulaire 4 de la SEC Formulaire 13D de la SEC
Gestion	10 ans	L'équipe dirigeante Conseil d'administration	Formulaire 10-K de la SEC Formulaire SEC DEF 14A
Principaux développements	10 ans	Annonces de l'entreprise	Formulaire 8-K de la SEC

^* exemple pour les titres américains, pour les titres non-américains des formulaires et sources réglementaires équivalents sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). Pour en savoir plus , cliquez ici.

Modèle d'analyse et flocon de neige

Les détails du modèle d'analyse utilisé pour générer ce rapport sont disponibles sur notre page Github. Nous avons également des guides sur la façon d'utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur .

Sources des analystes

Mesoblast Limited est couverte par 25 analystes. 6 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

Analyste	Institution
Dennis Hulme	APP Securities Pty Ltd.
Russell Wright	Barclay Pearce Capital Pty Limited
Stuart Roberts	Bell Potter

Mesoblast Bilan de santé

Santé financière contrôle des critères 4/6

Informations clés

Mises à jour récentes de la santé financière

Mesoblast Limited Auditor Raises 'Going Concern' Doubt

Recent updates

Mesoblast Limited has completed a Follow-on Equity Offering in the amount of AUD 1.511944 million.

Mesoblast Finally Gets Its Approval In GVHD: Where Now?

Mesoblast Limited’s RYONCIL® is the First U.S. FDA-Approves Mesenchymal Stromal Cell (MSC) Therapy

FDA Grants Revascor (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation in Children with Congenital Heart Disease

Mesoblast Limited Announces Publication in the November 2024 Online Issue of the European Journal of Heart Failure

Mesoblast Limited, Annual General Meeting, Nov 15, 2024

Mesoblast: Undervalued Due To Remestemcel-L's Substantial Growth Potential

Mesoblast Limited Announces the United States Food and Drug Administration Has Accepted Its Biologics License Application (Bla) Resubmission for Ryoncil®

Mesoblast Limited Announces Patient Enrollment Commences in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain

Mesoblast: Rolling The Dice On Cellular Medicines

Mesoblast Limited Resources Biologics Licence Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil in the Treatment of Children with SR-aGVHD

Mesoblast to File Biologics License Application for Ryoncil FDA Approval Next Week

Mesoblast Limited: Back From The Dead

United States Food & Drug Administration Notifies Mesoblast Limited of Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease

Mesoblast Limited has completed a Follow-on Equity Offering in the amount of AUD 0.93 million.

Mesoblast Limited has completed a Follow-on Equity Offering in the amount of AUD 97.041224 million.

Mesoblast Limited Announces United States Food & Drug Administration Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with A Left Ventricular Assist Device

United States Food & Drug Administration Grants Mesoblast Rare Pediatric Disease Designation for Revascor®? (Rexlemestrocel-L) in Children with Congenital Heart Disease

Mesoblast Limited, Annual General Meeting, Nov 28, 2023

Jane Bell AM Appointed Chair of Mesoblast Audit and Risk Committee

Mesoblast Limited Provides an Update on the Path to Approval for Its Lead-Product Candidate Remestemcel-L in the Treatment of Pediatric and Adult Steroid-Refractory Acute Graft Versus Host Disease

Mesoblast Limited Receives Complete Response from U.S. Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children

Mesoblast Limited Appoints Dr. Philip R. Krause, Member of the Board of Directors, to Formal Strategic Advisory Role

Remestemcel-L Clinical and Potency Studies Presented At Premier Meeting of Transplantation Research and Therapy

Mesoblast Limited Announces FDA Grants Regenerative Medicine Advanced Therapy Designation for Rexlemestrocel-L in Chronic Low Back Pain

Mesoblast Limited Resubmits Biologic License Application to FDA for Remestemcel-L in Children With Steroid-Refractory Acute Graft Versus Host Disease (Sr-aGVHD)

Mesoblast Limited Announces Top-Line Long-Term Survival Results for Remestemcel-L from its Pivotal Phase 3 Trial (GVHD-001) in Children with Steroid-Refractory Acute Graft-Versus-Host Disease

Mesoblast Limited, Annual General Meeting, Nov 23, 2022

Mesoblast Limited Submits New Information to FDA File in Response to Items in the CRL to the Remestemcel-L BLA for SR-aGVHD

Mesoblast GAAP EPS of -$0.14, revenue of $10.21M

Mesoblast Limited Announces Board Changes

Mesoblast Limited Announces Single Intervention with Rexlemestrocel-L Improves Left Ventricular Ejection Fraction At 12 Months, Preceding Long-Term Reduction in Major Adverse Cardiovascular Events

Mesoblast Limited Provides Litigation Update

Mesoblast Limited Provides Update on Survival Outcomes in Covid-19 ARDS Patients Treated with Remestemcel-L

Mesoblast Limited Announces Class Action Proceeding in the Federal Court of Australia

Mesoblast Limited Announces Executive Changes

Donal O'Dwyer Retires from the Board of Mesoblast Limited

Mesoblast Limited Announces Positive Results from an Interim Analysis of the First Patient Cohort in the Randomized, Controlled Study of Remestemcel-L by Direct Endoscopic Delivery to Areas of Inflammation in Patients with Medically Refractory Ulcerative Colitis or Crohn's Colitis

Mesoblast Limited Appoints Eric Rose as Chief Medical Officer

Mesoblast Limited Announces 36-Month Results of Phase 3 Trial in Chronic Low Back Pain

Mesoblast Provides Update Following Meeting with FDA’s OTAT on Remestemcel-L for Children with Acute Graft Versus Host Disease

Mesoblast Limited Receives Feedback from the US Food & Drug Administration’S Office of Tissues and Advanced Therapies on the Phase 3 Program of Rexlemestrocel-L

Mesoblast Limited announced that it expects to receive $90 million in funding from Oaktree Capital Management, L.P.

Mesoblast Presents Respiratory Function Results of COVID-19 ARDS Trial at Pulmonary Disease Conference

Mesoblast Limited Provides Update on Program for Chronic Low Back Pain Due to Degenerative Disc Disease

Mesoblast Limited Improves Outcomes in Inflammatory Lung Disease with Remestemcel-L Published in Respiratory Research Journal

Mesoblast Limited Announces the 60 Day Results from the Randomized Controlled Trial of remestemcel-L in 222 Ventilator-Dependent COVID-19 Patients with Moderate/Severe Acute Respiratory Distress Syndrome (ARDS) Which Had Been Halted After the Third Interim Analysis

Mesoblast's remestemcel-L reduces mortality by 46% in patients under age 65 with COVID-19 ARDS

Mesoblast Limited announced that it expects to receive AUD 138.251367 million in funding

Mesoblast Limited Announces Positive Outcomes of First Children Treated with Remestemcel-L for Multisystem Inflammatory Syndrome (MIS-C) and Heart Failure Post-Covid-19 Published in Pediatrics

Mesoblast Limited Announces Results from the Phase 3 Randomized Controlled Trial of Its Allogeneic Mesenchymal Precursor Cell Therapy

Mesoblast issues FQ2 operational and financial update

Mesoblast Limited Presents Heart Failure Phase 3 Trial Results At Investor Healthcare Conference

Mesoblast Limited Announces Additional Results from the Landmark Dream-Hf Randomized Controlled Phase 3 Trial in 537 Treated Patients with Chronic Heart Failure with Reduced Left Ventricular Ejection Fraction (HFrEF) Who Received Rexlemestrocel-L (REVASCOR) or Control Sham

Mesoblast's rexlemestrocel-l reduces heart attacks, strokes

Mesoblast: The Future Looks Bleak

Mesoblast Limited Announces Update on Covid-19 ARDS Trial

Mesoblast Provides Topline Results From Phase 3 Trial of Rexlemestrocel-L for Advanced Chronic Heart Failure

Mesoblast fails to meet primary endpoint of reduction in recurrent non-fatal heart failure events

Mesoblast Limited Announces United States Food and Drug Administration Granted Fast Track Designation for Remestemcel-L in the Treatment of Acute Respiratory Distress Syndrome Due to Covid-19 Infection

Mesoblast Limited Announces FDA Grants Fast Track Designation for Remestemcel-L in the Treatment of Acute Respiratory Distress Syndrome Due to COVID-19

Mesoblast cell therapy Fast Track'd for COVID-19-related acute respiratory distress syndrome; shares up 14%

Mesoblast Limited announced that it expects to receive $25 million in funding from Novartis AG

Mesoblast Limited Enters into an Exclusive Worldwide License and Collaboration Agreement with Novartis for the Development, Manufacture and Commercialization of Remestemcel-L

Mesoblast EPS beats by $0.22, misses on revenue

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been File Against Precigen, Royal Caribbean, Mesoblast and Loop Industries

The Law Offices of Frank R. Cruz Announces Class Action Lawsuit Against Mesoblast Limited

Rosen Law Firm Reminds Mesoblast Limited Investors of Important Deadline

Mesoblast Limited Announces Phase 3 Trial in COVID-19 ARDS Surpasses 50% Enrollment

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Mesoblast Limited

Mesoblast Limited Announces US Food and Drug Administration Issues Complete Response Letter to its Biologics License Application

Mesoblast Limited Announces Updates on RYONCIL

Mesoblast Limited Receives Complete Response Letter from US Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children

Mesoblast Limited Auditor Raises 'Going Concern' Doubt